Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study
- Resource Type
- Correspondence
- Authors
- Heiblig, Maël; Ferrada, Marcela A. ; Koster, Matthew T. ; Barba, Thomas ; Gerfaud-Valentin, Mathieu; Mékinian, Arsène; Coelho, Henrique; Fossard, Gaelle; Barraco, Fiorenza; Galicier, Lionel; Bienvenu, Boris; Hirsch, Pierre; Vial, Guillaume; Boutin, Anne Blandine; Galland, Joris; Le Guenno, Guillaume; Bigot, Adrien; Warrington, Kenneth J.; Kermani, Tanaz A.; Grayson, Peter C.; Patel, Bhavisha A.; Beck, David B.; Jamilloux, Yvan; Fenaux, Pierre; Sujobert, Pierre
- Source
- In Blood 25 August 2022 140(8):927-931
- Subject
- Language
- ISSN
- 0006-4971